Alar Pharmaceuticals (ROCO:6785) Common Stock: NT$668.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6785 Alar Pharmaceuticals Inc ROCO:6785
53 GF Score
Price NT$108.50
GF Value NT$96.24
Valuation Modestly Overvalued
! 2 Warning Signs
View Full Analysis

What is Alar Pharmaceuticals Common Stock?

Alar Pharmaceuticals ROCO:6785 +1.35% 53 Common Stock is NT$668.00 Mil as of Mar. 2026. GuruFocus rates ROCO:6785 with a GF Score™ of 53/100 and a GF Value™ of NT$96.24 (Modestly Overvalued). The stock has 2 warning signs investors should review.

Alar Pharmaceuticals's quarterly common stock stayed the same from Sep. 2025 (NT$668.00 Mil) to Dec. 2025 (NT$668.00 Mil) and stayed the same from Dec. 2025 (NT$668.00 Mil) to Mar. 2026 (NT$668.00 Mil).

Alar Pharmaceuticals's annual common stock increased from Dec. 2023 (NT$570.00 Mil) to Dec. 2024 (NT$668.00 Mil) but then stayed the same from Dec. 2024 (NT$668.00 Mil) to Dec. 2025 (NT$668.00 Mil).

Alar Pharmaceuticals Common Stock Historical Data

* Premium members only.

The historical data trend for Alar Pharmaceuticals's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alar Pharmaceuticals Common Stock Chart

Alar Pharmaceuticals Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Common Stock
Get a 7-Day Free Trial Premium Member Only 570.00 570.00 570.00 668.00 668.00

Alar Pharmaceuticals Quarterly Data
Dec20 Jun21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 668.00 668.00 668.00 668.00 668.00
ROCO:6785
53GF Score
Alar Pharmaceuticals Inc ROCO:6785
Common Stock is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alar Pharmaceuticals Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Frequently Asked Questions Learn more about Common Stock →
What does a Common Stock of NT$668.00 Mil mean?
Alar Pharmaceuticals (ROCO:6785) has a Common Stock of NT$668.00 Mil as of Mar. 2026. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Alar Pharmaceuticals and its competitors.
Is Alar Pharmaceuticals' Common Stock too high?
Alar Pharmaceuticals' current Common Stock is NT$668.00 Mil. Overall, Alar Pharmaceuticals has a GF Score™ of 53/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Alar Pharmaceuticals' Common Stock compare to ZTS and UTHR?
Alar Pharmaceuticals' Common Stock of NT$668.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Common Stock for a Drug Manufacturers company?
A good Common Stock depends on the Drug Manufacturers industry context. However, Common Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Common Stock mean?
A high Common Stock can signal that a stock is expensive relative to its fundamentals. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Alar Pharmaceuticals and its competitors. Alar Pharmaceuticals's current Common Stock is NT$668.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alar Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Alar Pharmaceuticals (ROCO:6785) is currently considered Modestly Overvalued. The stock's GF Value™ is NT$96.24, compared to a current price of NT$108.50 — trading 12.7% above its estimated fair value. The current Common Stock is NT$668.00 Mil. Alar Pharmaceuticals' overall GF Score™ is 53/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Common Stock calculated?
Common Stock is calculated from a company's financial statements. For Alar Pharmaceuticals (ROCO:6785), the current Common Stock is NT$668.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Alar Pharmaceuticals (ROCO:6785) Overvalued in 2026?

Based on GuruFocus' analysis, Alar Pharmaceuticals stock appears to be overvalued. The current stock price of NT$108.50 is trading 12.7% above its estimated GF Value™ of NT$96.24. GuruFocus considers Alar Pharmaceuticals to be Modestly Overvalued.

Key valuation signals for ROCO:6785:

  • Common Stock: NT$668.00 Mil
  • GF Value™: NT$96.24 vs. price of NT$108.50 (12.7% above fair value)
  • GF Score™: 53/100 with 2 warning signs

No single metric tells the full story. See the ROCO:6785 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Alar Pharmaceuticals Business Description

Address Jhongke Road, No. 32, No. 2, 5th Floor, Situn District, Taichung, TWN, 428015
Alar Pharmaceuticals Inc is a drug development company mainly engaged in the research and development of new drugs, sales of western pharmaceuticals, and medical devices. It focuses on developing long-acting release drug products for CNS disorders and chronic diseases, which mainly include opioid use disorder, chronic pain, and depressive disorder. The company currently has only a new drug development division, and its product pipeline comprises various drug candidates such as ALA-1000 (Buprenorphine), ALA-1300, ALA-2000 (Naltrexone), ALA-3000 (Ketamine), ALA-4000 (Apomorphine), and ALA-5000 (Third-generation antipsychotic). Geographically, the company generates maximum revenue from the USA and also has its presence in Taiwan and the United Kingdom.
53GF Score

Get the complete analysis for ROCO:6785

Common Stock is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$108.50
Price
NT$96.24
GF Value